Antiproteinuric Effect of Oral Calcitriol in chronic Proteinuric Nephropathy:A randomized controlled trial.

ICMR0 个研究点目标入组 90 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Normal blood pressure on stable doses of antihypertensive drugs for 1 month
•2.Estimated GFR 30 -90 ml/min/1.73 m2
•3.Children on corticosteroid should be on stable doses of corticosteroids for last 2 month

•Following children will be excluded from the study.
•1.Patients below 3 years of age
•2.Patients with estimated GFR 30 ml/min/1.73m2
•3.Patients with chronic liver disease or deranged transaminase levels (more than 2 times the normal)
•4.Patients with phosphorus levels 5.5 mg/dl, current hypercalcemia (serum calcium 10.5 mg/dl) or untreated primary hyperparathyroidism.
•5.Patients with hypercalciuria (24 h urinary calcium 4 mg/kg/d)
•6.Children residing outside 200km of the Delhi border.
•7.History of nephrolithiasis.
•8.Known malabsorption syndromes, e.g., celiac disease, active inflammatory bowel disease, etc.
•9.Treatment with vitamin D or any of its active metabolites in last 4 weeks
•10.Treatment with any drug which may interfere with vitamin D metabolism, e.g., phenobarbital, phenytoin.
•11.Patients with bilateral renal artery stenosis.
•12.Patients on immunosuppressive drugs such as cyclophosphamide, calcineurin inhibitors, azathioprine
•13.Steroid responsive nephrotic syndrome
•14.Patients on high dose (2 mg/kg/d prednisolone or equivalent) or intravenous corticosteroids

发起方

ICMR